When science hits the headlines, we seek the views of expert sources who assess the news rigorously and quickly, according to the available evidence.
A study of more than 700,000 people in Sweden analysed the effectiveness of the heterologous schedule, combining the AstraZeneca vaccine with another dose of a messenger RNA vaccine, with the traditional homologous schedule, consisting of two doses of AstraZeneca. The results showed increased protection against SARS-CoV-2 infection when two different vaccines were combined.
The European Medicines Agency issued its recommendations yesterday afternoon regarding the administration of a third dose of the Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) vaccines. These are the reactions of several experts on the matter.
Johnson & Johnson has just released preliminary data from its two-dose trial in a press release. It shows that the second dose increases the antibody response and also confirms the duration of protection among those who received one dose.